Page 156«..1020..155156157158..170180..»

U.S. Patent & Trademark Office Allows AVEO Oncology’s Patent Application Covering Use of FOTIVDA® for the Treatment of Refractory Advanced…

Posted: October 13, 2022 at 2:26 am

BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced today that, as disclosed on uspto.gov, the United States Patent and Trademark Office (“USPTO”) has allowed U.S. Patent Application No. 17/720,619, titled “Use of Tivozanib to Treat Subjects with Refractory Cancer” (the “Application”). AVEO expects to receive a Notice of Allowance for this Application. This Application will potentially issue as a patent in 2022 and will provide patent protection in the United States for the claimed methods of use of FOTIVDA into 2039.

See the rest here:
U.S. Patent & Trademark Office Allows AVEO Oncology’s Patent Application Covering Use of FOTIVDA® for the Treatment of Refractory Advanced...

Posted in Global News Feed | Comments Off on U.S. Patent & Trademark Office Allows AVEO Oncology’s Patent Application Covering Use of FOTIVDA® for the Treatment of Refractory Advanced…

SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of Monkeypox

Posted: October 13, 2022 at 2:26 am

NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today provided an update on the status of multiple clinical trials now underway to assess the safety and efficacy of TPOXX to treat monkeypox.

Original post:
SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of Monkeypox

Posted in Global News Feed | Comments Off on SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of Monkeypox

23andMe to Present at Upcoming Investor Conferences

Posted: October 13, 2022 at 2:26 am

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that management will be participating in investor presentations at the following conferences:

Original post:
23andMe to Present at Upcoming Investor Conferences

Posted in Global News Feed | Comments Off on 23andMe to Present at Upcoming Investor Conferences

AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen® in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions

Posted: October 13, 2022 at 2:26 am

Company expects to commence patient enrollment and dosing in Q1 2023 Company expects to commence patient enrollment and dosing in Q1 2023

More here:
AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen® in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions

Posted in Global News Feed | Comments Off on AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen® in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions

Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2

Posted: October 13, 2022 at 2:26 am

•  No safety concerns noted in ongoing clinical trial•  Study timeline remains on track

Read the original:
Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2

Posted in Global News Feed | Comments Off on Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2

BioSyent Initiates First Dividend

Posted: October 13, 2022 at 2:26 am

MISSISSAUGA, Ontario, Oct. 12, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on December 15, 2022, to shareholders of record at the close of business on November 30, 2022. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors.

See the article here:
BioSyent Initiates First Dividend

Posted in Global News Feed | Comments Off on BioSyent Initiates First Dividend

Enterin and Parkinson’s UK Announce Research Collaboration in Parkinson’s Dementia

Posted: October 13, 2022 at 2:26 am

PHILADELPHIA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company developing novel treatments for neurodegenerative and metabolic diseases announces a collaboration with the Parkinson’s Virtual Biotech, the drug development and discovery arm of Parkinson's UK. A new phase 2 trial will study the effects of ENT-01 on Parkinson’s Disease (PD)-associated dementia.

See more here:
Enterin and Parkinson’s UK Announce Research Collaboration in Parkinson’s Dementia

Posted in Global News Feed | Comments Off on Enterin and Parkinson’s UK Announce Research Collaboration in Parkinson’s Dementia

ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China

Posted: October 13, 2022 at 2:26 am

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

Go here to read the rest:
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China

Posted in Global News Feed | Comments Off on ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China

Basilea announces late breaking presentation on the successfully completed ERADICATE phase 3 study with ceftobiprole in Staphylococcus aureus…

Posted: October 13, 2022 at 2:26 am

Basel/Allschwil, Switzerland, October 13, 2022

Read the original post:
Basilea announces late breaking presentation on the successfully completed ERADICATE phase 3 study with ceftobiprole in Staphylococcus aureus...

Posted in Global News Feed | Comments Off on Basilea announces late breaking presentation on the successfully completed ERADICATE phase 3 study with ceftobiprole in Staphylococcus aureus…

BSGM – The British Society for Genetic Medicine

Posted: October 13, 2022 at 2:26 am

Closing Date: 30/10/2022Location: Oxford Genetics Laboratory

The Oxford Genetics Laboratories (OGL) have a rare and exciting opportunity for an individual with relevant experience to join us as a Principal Clinical Scientist in Bioinformatics. OGL works in partnership with West Midlands and Wessex laboratories to form the Central & South Genomic Laboratory Hub (C&SGLH), and provides state-of-the-art molecular and cytogenetic diagnostic testing for core and specialist rare disease services, and for acquired disorders. We undertake a comprehensive range of investigations that includes NGS analysis using in-house pipelines, and WGS interpretation. OGL also collaborates closely with many of the genetic research leaders in Oxford, as well as the NIHR Oxford Biomedical Research Centre. The successful candidate will lead a small Bioinformatics team and contribute to the overall management and direction of the OGL, particularly with regards to data security. Additionally, you will participate in C&SGLH and NHSE bioinformatic forums to inform the OGL bioinformatic strategy, and may take on other relevant professional roles, for example in training. We are keen to hear from Registered Clinical Bioinformaticians, as well as from people with relevant transferrable skills who have worked in the private sector or academia. This is a permanent full-time post (37.5hrs) but applicants wishing to work part-time will be considered. The OGL is open 8am to 6pm Monday to Friday, and the working pattern is expected to be within these times. The Principal Bioinformatician undertakes a broad range of bioinformatic, analytical and administrative duties with a considerable degree of autonomy, assuming responsibility for all aspects of the bioinformatic services including developing and implementing a robust bioinformatics strategy to meet the needs of a large multi-disciplinary laboratory. They will also ensure secure yet accessible data storage, and be responsible for laboratory-wide organisation, monitoring, co-ordination and achievement of specific bioinformatic targets, with responsibility for all bioinformatic staff within the department. They are required to ensure delivery of a computational framework that has the flexibility and robustness to deliver expert analysis of complex data generated using the latest sequencing technologies, and will perform highly accurate and skilled analysis with often unpredictable outcomes and requiring periods of intense concentration. The role involves continued development of bioinformatics strategy and requires networking with peers and a deep understanding of the molecular biology and computational processes of NGS data generation. He/she must be able to effectively trouble-shoot any potential data quality issues, and communicate complex bioinformatic, scientific and confidential information to colleagues in electronic, written and verbal forms. Bioinformaticians also participate in teaching and training and are expected to remain up-to-date with their field.

Carl FratterEmail: Carl.Fratter@ouh.nhs.ukWebsite: http://jobs.ouh.nhs.uk/job/v4528933

Genetics Laboratory, Churchill HopsitalOxfordOxonOX3 7LE

Go here to see the original:
BSGM - The British Society for Genetic Medicine

Posted in Genetic medicine | Comments Off on BSGM – The British Society for Genetic Medicine

Page 156«..1020..155156157158..170180..»